Научная литература
booksshare.net -> Добавить материал -> Медицина -> Насонов Е.Л. -> "Антифосфолипидный синдром" -> 121

Антифосфолипидный синдром - Насонов Е.Л.

Насонов Е.Л. Антифосфолипидный синдром — М.: Литтерра, 2004. — 440 c.
ISBN 5-98216-010-5
Скачать (прямая ссылка): antisindrom2004.pdf
Предыдущая << 1 .. 115 116 117 118 119 120 < 121 > 122 123 124 125 126 127 .. 184 >> Следующая

92. Blann AD, Arniral J, McCollum CN. Increased soluble thrombomodulin and soluble E-selectin as predictors of disease following myocar-dial infarction. Eur J Haematol 1997; 58: 15— 120.
93. Hillis GS, Terregino CA, Taggart P, et al. P-selectin is a powefull predictor of early events in patients with chest pain resume due to myocardial ischemia. Circulation 2000; 102 (Suppl): II— 499.
94. Ikeda H, Takajo Y, Ichiki K, et al. Increased soluble form of P-selectins in blood of patients with unstable angina. Circulation 1995; 92: 1693—1696.
95. Sakurai S, Inoue A, Koh CS, et al. Soluble form of selectins in blood of patients with acute myocardial infarction and coronary intervention. Vasc Med 1997; 2:163—168.
96. Shimomura H, Ogawa H, Arai H, et al. Serial changes in plasma levels of soluble P-selectin in patients with acute myocardial infarction. Am J Cardiol 1998; 81:163—168.
97. Chong BH, Murray B, Berndt MC, et al. Plasma P-selectin is increased in thrombotic consumptive disorders. Blood 1994; 83: 1535—1541.
98. Blann AD, Faragher EB, McCollum CN. Increased soluble P-selectin in ischemic heart disease: a new marker for the progression of atherosclerosis. Blood Coagul Fibrinolysis 1997; 8: 383—390.
99. van der Meer IM, de Maat MPM, Bots ML, et al. Inflammatory mediators and cell adhesion molecules as indicator of severity of atherosclerosis, The Rotterdam stury. Arteriolscler Thromb Vasc Biol 2002; 22: 838—842.
100. Blann AD, Miller JP, McCollum CN. von Willebrand factor and soluble E-selectin in the predictor of cardiovascular disease progression in hyperlipidemia. Atherosclerosis 1997; 132: 151— 156.
101. Wiman B, Andersson T, Hallqvist J, et al. Plasma levels of tissue plasminogen activator/ plasminogen activator inhibitor1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arteriolscler Thromb Vasc Biol 2000; 20: 2019— 2025.
102. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J1991; 66:351—355.
103. Rumley A, Lowe GDO, Sweetman PM, et al. Factor VIII, von Willebrand factor and risk of major ischemic heart disease in the Caerphilly Heart Study. Br J Haematol 1999; 105:110—116.
104. Jager A, van Hinsberg VWM, Kostense PJ, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects. The Hoorn study. Artheriolscler Thromb Vasc Biol 1999; 19: 3071—3078.
105. Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predict
SHS-OOO4.qxd 21.11.2006 16:56 Page 2998
Q-
Насонов Е.Л. Антифосфолипидный синдром.
adverse outcome in unstable coronary artery disease. Beneficial effects of enoxaparine. Circulation 1998; 98: 294—299.
106. Atherosclerosis and autoimmunity. Ed. Y. Shoenfeld, D. Harats, G. Wick. Elsevier, 2001.
107. Насонов ЕЛ. Проблема атеротромбо-за в ревматологии. Вестник РАМН, 2003; 7: 6—10.
108. Holvoet P, Vanhaecke J, Janssens S, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998; 98: 1487—1494.
109. Huthe J, Fagerberg B, Circulating oxidized LDL is associated with sublinical atherosclerosis development and inflammatory cytokines (AIR Study). Atheroscler Thromb Vasc Biol 2002; 22: 1162—1167.
110. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883—887.
111. Purrunen M, Manttari M, Manninen V, et al. Antibody against oxidized low-density lipopro-tein predicting myocardial infarction. Arch Intern Med 1994; 154: 2605—2609.
112. Vaarala O, Manttari M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23—27.
113. Wu R, Nityanand S, Berglund L, et al. Antibodies against cardiolipin and oxidative modified LDL in 50-year-old man predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17: 3159—3165.
114. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, et al. Crossreaction between antibodies to oxidised low-density lipoprotein and cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923—925.
115. Vaarala O, Puurunen M, Manttari M, et al. Antibodies to protrombin imply a risk of
myocardial infarction in middle-aged men. Thromb Haemost 1996; 75: 456—459.
116. Farsi A, Domeneghetti MP, Brunelli T, et al. Activation of the immune system and coronary artery disease: the role of anti-endothelial cell antibodies. Atherosclerosis 2001; 154: 429—
117. Zhu J, Quyyumi AA, Rott D, et al. Antibodies to human heart-shock protein are associated with the presence and severity of coronary artery disease. Evidence for an autoimmune component of atherogenesis. Circulation 2001; 103:1071—1075.
118. Inoue T, Uchida T, Kamishirado H, et al. Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease. J Am Coll Cardiol 2001; 37: 1871—1886.
Предыдущая << 1 .. 115 116 117 118 119 120 < 121 > 122 123 124 125 126 127 .. 184 >> Следующая

Реклама

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed

Есть, чем поделиться? Отправьте
материал
нам
Авторские права © 2009 BooksShare.
Все права защищены.
Rambler's Top100

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed